At the Forefrontof Fintech.

Wilson Sonsini represented Blockstack in the first-ever offering of a cryptocurrency token to be either qualified or registered under federal securities laws of the U.S. for sale to the public.

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For more than six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Introducing Neuron, a new platform that streamlines, automates, and digitizes the typical legal processes along a start-up’s journey

Neuron Website

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

News Articles

Firm Ranked Highly in 2022 BTI Associate Satisfaction A-Listers Survey

News Articles

Firm Named Finalist for The American Lawyer Industry Awards

Alerts

New York Attorney General Sues CVS over “Brazenly Anticompetitive Tying Scheme” in Provision of 340B Services

Leading Matters

Client Highlights

Wilson Sonsini Advises MiroBio on Patent Matters Related to Acquisition by Gilead

On August 4, 2022, Gilead Sciences and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

Learn More

Client Highlights

Wilson Sonsini Advises Eneus Energy on Investment Agreement with Carlyle and GIC

On August 4, 2022, Eneus Energy, a green ammonia project development company, announced a strategic investment from Carlyle and GIC. Wilson Sonsini Goodrich & Rosati served as legal counsel to Eneus, drawing on the experience of a cross-border team from the firm’s Seattle, San Francisco, and London offices. Taylor Wessing served as special counsel on certain UK tax and other matters.

Learn More

Client Highlights

Wilson Sonsini Advises Investors on Rhombus Energy’s Acquisition by BorgWarner

On August 3, 2022, BorgWarner inc. (BWA), an automotive supplier, announced it has acquired Rhombus Energy Solutions, an energy management systems provider, for up to $185 million. The consideration is being funded primarily with cash balances of the acquirer, with approximately $130 million delivered at closing. The remaining amount of up to $55 million could be paid in the form of contingent payments over the next three years.

Learn More

Client Highlights

Wilson Sonsini Advises Control Risks on Launch of Seerist

On August 2, 2022, Seerist, Inc. launched as the world's leading solution provider of augmented analytics for security and threat intelligence professionals. The new company merges Control Risks' CORE online platform with the machine learning backbone from U.S.-based Geospark Analytics' Hyperion platform. Seerist provides the only augment analytics solution that integrates continuous-learning with expert, in-location human analysis with artificial intelligence (AI) algorithms specifically designed to deliver early, actionable, and strategic insight for corporations, non-governmental organizations (NGOs), and government organizations. Wilson Sonsini Goodrich & Rosati represented Control Risks in the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises The Newcastle Network on Kizik's $20 Million Series B Round

On July 19, 2022, Kizik, a leader in hands-free shoes, and its parent, HandsFree Labs, announced the completion of a $20 million Series B funding round. Kizik will use the funds to launch a Kizik Kids line and create a retail footprint with Kizik stores. The funding round was led by The Newcastle Network, a consumer-focused private equity fund combining expertise in data science, creator and social media marketing, innovation, and entrepreneurship to help companies unlock new levels of growth.

Learn More

Client Highlights

Wilson Sonsini Advises Replay on IP Strategy Related to Launch, $55 Million Seed Funding

On July 25, 2022, Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced its launch with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Wilson Sonsini Goodrich & Rosati has been a long-term adviser to Replay on its IP strategy.

Learn More

See More Leading Matters

The Life Sciences Report – June 2022

This latest issue features articles on the firm’s new Boulder office and recent Gateway to Colorado VC roadshow, a collaboration between Deloitte’s Center for Health Solutions and MedTech Innovator to evaluate trends across the medical technology start-up landscape, and life sciences venture financings in which clients participated across the first half and second halves of 2021. It also includes an update on the priority fight between UC and the Broad Institute over CRISPR gene editing patents, articles addressing patented inventions under the patent safe harbor of Section 271(e)(1) and the firm’s partnership with Bakar Labs, and a summary of select recent life sciences client highlights and upcoming events.